Clinical Trial Update: Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) [Phase 2]

View source ↗

Summary

The phase 2 TIDAL trial of Zandelisib (ME-401) in follicular lymphoma, non-Hodgkin lymphoma, and marginal zone lymphoma was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Zandelisib (zandelisib)

Snippet

Sponsor: MEI Pharma, Inc. | Conditions: Follicular Lymphoma (FL), Non Hodgkin Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2024-02-01